MilliporeSigma
  • Home
  • Search Results
  • A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

Science translational medicine (2015-08-21)
Karuppiah Muthumani, Darryl Falzarano, Emma L Reuschel, Colleen Tingey, Seleeke Flingai, Daniel O Villarreal, Megan Wise, Ami Patel, Abdullah Izmirly, Abdulelah Aljuaid, Alecia M Seliga, Geoff Soule, Matthew Morrow, Kimberly A Kraynyak, Amir S Khan, Dana P Scott, Friederike Feldmann, Rachel LaCasse, Kimberly Meade-White, Atsushi Okumura, Kenneth E Ugen, Niranjan Y Sardesai, J Joseph Kim, Gary Kobinger, Heinz Feldmann, David B Weiner
ABSTRACT

First identified in 2012, Middle East respiratory syndrome (MERS) is caused by an emerging human coronavirus, which is distinct from the severe acute respiratory syndrome coronavirus (SARS-CoV), and represents a novel member of the lineage C betacoronoviruses. Since its identification, MERS coronavirus (MERS-CoV) has been linked to more than 1372 infections manifesting with severe morbidity and, often, mortality (about 495 deaths) in the Arabian Peninsula, Europe, and, most recently, the United States. Human-to-human transmission has been documented, with nosocomial transmission appearing to be an important route of infection. The recent increase in cases of MERS in the Middle East coupled with the lack of approved antiviral therapies or vaccines to treat or prevent this infection are causes for concern. We report on the development of a synthetic DNA vaccine against MERS-CoV. An optimized DNA vaccine encoding the MERS spike protein induced potent cellular immunity and antigen-specific neutralizing antibodies in mice, macaques, and camels. Vaccinated rhesus macaques seroconverted rapidly and exhibited high levels of virus-neutralizing activity. Upon MERS viral challenge, all of the monkeys in the control-vaccinated group developed characteristic disease, including pneumonia. Vaccinated macaques were protected and failed to demonstrate any clinical or radiographic signs of pneumonia. These studies demonstrate that a consensus MERS spike protein synthetic DNA vaccine can induce protective responses against viral challenge, indicating that this strategy may have value as a possible vaccine modality against this emerging pathogen.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tetrazolium Blue Chloride, used in colorimetric determination of reducing compounds
Sigma-Aldrich
5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt, tablet
Sigma-Aldrich
5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt, ≥99% (HPLC)
Sigma-Aldrich
5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt, BioReagent, for molecular biology, powder, ≥99%
Sigma-Aldrich
5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt, ≥95.0% (HPLC)
Sigma-Aldrich
Tetrazolium Blue Chloride, indicator for germination, suitable for microbiology, ≥90% (T)
Sigma-Aldrich
o-Phenylenediamine, flaked, 99.5%
Sigma-Aldrich
Brefeldin A, ≥99% (HPLC and TLC), BioXtra, for molecular biology
Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, ≥99% (HPLC and TLC)
Sigma-Aldrich
o-Phenylenediamine, Peroxidase substrate, ≥98.0%, powder
Sigma-Aldrich
o-Phenylenediamine dihydrochloride, peroxidase substrate
Sigma-Aldrich
Aphidicolin from Nigrospora sphaerica, ≥98% (HPLC), powder
Sigma-Aldrich
o-Phenylenediamine, tablet, 20 mg substrate per tablet
Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, Ready Made Solution, 10 mg/mL in DMSO
Sigma-Aldrich
o-Phenylenediamine, sublimed, ≥99%
Sigma-Aldrich
Diethyl azodicarboxylate solution, 40 wt. % in toluene